Shots:Eli Lilly has reported 2yrs. data from VIVID-2 (OLE) study (incl. 1yr. of VIVID-1) of Omvoh for mod. to sev. Crohn's disease; regulatory review is underway in China, Canada, Japan & other regions
In VIVID-1, 92.9% pts sustained clinical remission (CDAI) and 78.6% retained endoscopic remission (SES-CD ≤4 & ≥2-point decrease, with no…
